Crucell
In March 2005, Crucell N.V. and SingVax signed a license agreement for Crucell's PER.C6 ® technology, which offers a safe and efficient way to produce bio-pharmaceuticals. This will be used by SingVax for the development and commercialisation of an improved vaccine against Japanese Encephalitis.
Click here to see press release.
|
|
OctoPlus
In September 2005, SingVax and OctoPlus announced their collaboration to develop single-shot JE vaccine. SingVax will combine its work in manufacturing JE viral particles, with OctoPlus' proprietary delivery systems, for the controlled release of drugs and antigens.
Click here to see press release.
|
